Ferrlecit Generic To Get 3-Part Evaluation After FDA Worry On Therapeutic Equivalence
This article was originally published in The Pink Sheet Daily
Actavis’ version of Sanofi’s brand comes under scrutiny after EU guidance suggests generic iron formulations could have higher levels of labile iron and that study of plasma levels alone “may conceivably fail to detect relevant differences in the tissue distribution of iron.”
You may also be interested in...
Watson's own citizen petitions blocking generics won't be an obstacle, company says.
Our infographic illustrates the recommendations in FDA’s COVID-19 pandemic recovery and preparedness plan, ranging from strengthening the EUA process to managing the backlog of pending inspections.
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.